These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32978826)

  • 21. Predictors of biochemical response to somatostatin receptor ligands in acromegaly.
    Marazuela M; Martínez-Hernandez R; Marques-Pamies M; Biagetti B; Araujo-Castro M; Puig-Domingo M
    Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101893. PubMed ID: 38575404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
    Marques-Pamies M; Gil J; Valassi E; Hernández M; Biagetti B; Giménez-Palop O; Martínez S; Carrato C; Pons L; Villar-Taibo R; Araujo-Castro M; Blanco C; Simón I; Simó-Servat A; Xifra G; Vázquez F; Pavón I; García-Centeno R; Zavala R; Hanzu FA; Mora M; Aulinas A; Vilarrasa N; Librizzi S; Calatayud M; de Miguel P; Alvarez-Escola C; Picó A; Sampedro M; Salinas I; Fajardo-Montañana C; Cámara R; Bernabéu I; Jordà M; Webb SM; Marazuela M; Puig-Domingo M
    Front Endocrinol (Lausanne); 2023; 14():1269787. PubMed ID: 38027102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
    J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T; Astorga R; Catalá M;
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
    Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.
    Ozkaya HM; Comunoglu N; Sayitoglu M; Keskin FE; Firtina S; Khodzhaev K; Apaydin T; Gazioglu N; Tanriover N; Oz B; Kadioglu P
    Pituitary; 2018 Aug; 21(4):335-346. PubMed ID: 29455389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
    Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
    J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).
    Brunetti A; Antonini S; Saladino A; Lavezzi E; Zampetti B; Cozzi R
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
    van der Lely AJ; Kuhn E; Muhammad A; Coopmans EC; Neggers SJ; Chanson P
    Eur J Endocrinol; 2020 Jun; 182(6):D17-D29. PubMed ID: 32234975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-cadherin expression is associated with somatostatin analogue response in acromegaly.
    Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
    Fougner SL; Borota OC; Berg JP; Hald JK; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):458-65. PubMed ID: 17941904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.